Galectin Therapeutics to Present at 29th Annual ROTH Conference
March 09, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
March 06, 2017 08:30 ET
|
Galectin Therapeutics
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) --...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 08, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials
February 07, 2017 16:40 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and the Providence Cancer Center today...
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
February 01, 2017 08:10 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated...
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
December 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company...
Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases
November 10, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced its plans to...
Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
November 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis
October 07, 2016 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
September 27, 2016 16:15 ET
|
Galectin Therapeutics
Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) ...